Merus N.V. (MRUS): Price and Financial Metrics


Merus N.V. (MRUS)

Today's Latest Price: $12.99 USD

0.09 (0.70%)

Updated Oct 22 4:00pm

Add MRUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

MRUS Stock Summary

  • For MRUS, its debt to operating expenses ratio is greater than that reported by merely 7.5% of US equities we're observing.
  • With a price/sales ratio of 12.98, Merus NV has a higher such ratio than 88.98% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, Merus NV is reporting a growth rate of 126.41%; that's higher than 90.42% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Merus NV are SNSS, AVEO, PTCT, SILC, and FOLD.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to www.merus.nl.

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $12.99 52-week high $20.64
Prev. close $12.90 52-week low $10.18
Day low $12.58 Volume 60,400
Day high $13.02 Avg. volume 99,175
50-day MA $12.24 Dividend yield N/A
200-day MA $14.28 Market Cap 377.26M

Merus N.V. (MRUS) Company Bio


Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.


MRUS Latest News Stream


Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream


Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about Merus NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Merus EPS beats by $0.12, misses on revenue

Merus (MRUS): Q2 GAAP EPS of -$0.54 beats by $0.12.Revenue of $6.1M (-4.1% Y/Y) misses by $1.61M.Press Release...

Seeking Alpha | August 6, 2020

Merus nabs US Orphan Drug tag for Zeno in pancreatic cancer

The FDA has designated Orphan Drug status for Merus's ([[MRUS]] -0.9%) Zenocutuzumab (Zeno) for the treatment of pancreatic cancer.Zeno is a class bispecific antibody that potently binds to the HER2 and HER3 receptors, to potently block the interaction of HER3 with its ligand, neuregulin 1 (NRG1). Zeno is currently in global Phase 1/2...

Seeking Alpha | July 27, 2020

Merus Appoints Andrew Joe, M.D., as Chief Medical Officer

Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancerUTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the appointment of Andrew Joe, M.D., as Chief Medical Officer. Dr. Joe is a medical oncologist with extensive expertise in the development of immuno-oncology, antibody and targeted cancer therapies, and with broad leadership experience in oncology drug development.“Andrew is an accomplished R&D leader, and he will be instrumental in advancing our clinical pipeline of multispec...

Yahoo | July 27, 2020

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zenocutuzumab (Zeno) for the treatment of patients with pancreatic cancer.   Zeno is a first in class bispecific antibody that potently binds to the HER2 and HER3 receptors, to potently block the interaction of HER3 with its ligand, neuregulin 1 (NRG1).  Zeno has demonstrated promising early clinical responses in patients with previously treated pancreatic cancer harboring NRG1 gene fusions, as presented at the AACR/NCI/EORTC International Confe...

Yahoo | July 27, 2020

Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients

Caris to provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trialUTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, Texas, July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) and Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a collaboration to detect neuregulin 1 (NRG1) fusions in cancer patients. Under the agreement, Caris has agreed to perform whole exome sequencing of DNA and whole transcriptome sequencing of RNA for certain cancer patients, focusing on pancreatic cancer, to identify...

Yahoo | July 13, 2020

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo 9.90%
3-mo -3.64%
6-mo -20.06%
1-year -18.81%
3-year -20.74%
5-year N/A
YTD -7.74%
2019 0.57%
2018 -27.84%
2017 -8.10%
2016 N/A
2015 N/A

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.737 seconds.